Resalis Therapeutics raises €10m Series A to treat obesity
“With RES-010 we aim to provide a therapeutic that precisely reduces fat mass in obesity with the potential to extend the durability of existing therapies”
17-Jan-2024 -
Resalis Therapeutics announced the closing of a €10 million ($11 million) Series A financing round led by Sunstone Life Science Ventures with participation from existing investors including Claris Ventures and angel investors. The proceeds will be used to initiate and complete the first-in-human ...
antisense oligonucleotides
investments
lipid metabolism
+4